Guardant Health SEC Filings

Guardant Health director and Co‑Chief Executive Officer AmirAli Talasaz reported multiple transactions in the company's common stock. On 09/30/2025 he received 4,814 shares from vesting of restricted stock units and, separately the same day, 2,440 shares were retained by the company to satisfy tax withholding at a reported price of $62.48. On 10/01/2025 he received an additional 23,997 vested shares and 12,162 shares were retained for tax withholding at $62.65. After these reported transactions his beneficial ownership rose to 2,010,036 shares.

Steve E. Krognes, a director of Guardant Health, Inc. (GH), reported a transaction dated 09/30/2025 in which 154 shares were acquired following vesting of restricted stock units. The Form 4 shows the acquisition price as $0, reflecting conversion of vested RSUs into common stock. After the transaction, the filing reports 18,282 shares of common stock beneficially owned by Mr. Krognes and 1,389 RSU-linked derivative shares reported as beneficially owned. The RSU award was originally granted on 08/09/2022 and vested 25% on 06/30/2023, with the remaining 75% vesting in substantially equal monthly installments over the following three years. The Form 4 is signed by an attorney-in-fact on behalf of Mr. Krognes on 10/02/2025.

Helmy Eltoukhy, Co-Chief Executive Officer and director of Guardant Health (GH), reported multiple transactions on 09/30/2025 and 10/01/2025. He had restricted stock units vest that resulted in acquisitions of 4,814 and 23,997 shares (reported as acquisitions at $0), with the company retaining 2,440 and 12,162 shares respectively to satisfy tax-withholding obligations related to the vesting (sales at $62.48 and $62.65). After the reported activity, his beneficial ownership of common stock is shown as 2,149,870 shares following the 10/01/2025 transactions and 119,986 RSU-equivalent shares remaining reported as derivative holdings. The Form 4 is signed by an attorney-in-fact on behalf of Mr. Eltoukhy.

Insider awards to Guardant Health director Alex M. Azar II

Alex M. Azar II, identified as a director of Guardant Health (GH), received equity awards on 09/12/2025. The filing reports a stock option to purchase 10,532 shares with an exercise price of $54.895 and an option term through 09/12/2035. The option and a separate restricted stock unit (RSU) award for 6,604 shares both vest over four years (25% one year after grant, remainder monthly over three years). The Form 4 was signed by an attorney-in-fact on 09/26/2025. The filing shows direct beneficial ownership following the grants: 10,532 option shares and 6,604 RSU shares.

Alex M. Azar II filed an initial Form 3 reporting his role with Guardant Health, Inc. (GH) as a Director. The event date requiring the statement is 09/12/2025. The filing discloses 0 shares of common stock beneficially owned, reported as direct ownership. The form is signed by an attorney-in-fact on behalf of Mr. Azar on 09/26/2025.

Manuel Hidalgo Medina, a director of Guardant Health, Inc. (GH), reported transactions dated 09/17/2025 showing the acquisition of 232 restricted stock units (RSUs) at $0 pursuant to vesting (Transaction Code M). The Form 4 shows 1,083 shares of common stock held following a separate non-derivative entry and 7,889 shares beneficially owned following the reported derivative transactions. The filing notes the RSU award was granted on July 17, 2024 and vests over four years: 25% vested at the one-year anniversary and the remaining 75% vests monthly over the following three years. The form is signed by an attorney-in-fact on 09/18/2025.

Tariq Musa, a director of Guardant Health, reported two transactions in September 2025. On 09/15/2025 249 restricted stock units (RSUs) vested, converting into 249 common shares and increasing his derivative/underlying holdings. On 09/17/2025 he sold 116 common shares at $55.63 per share, reducing his direct common stock holdings from 7,707 to 7,591 shares. After these transactions, he beneficially owns 7,591 common shares directly and 4,498 shares underlying RSUs.

Myrtle S. Potter, a director of Guardant Health, Inc. (GH), reported an RSU vesting and a subsequent small sale of shares. On 09/15/2025 a restricted stock unit award vested for 68 shares at no cash price. Two days later, on 09/17/2025, the reporting person sold 26 shares at $55.63 per share. Beneficial ownership reported after the sale was 18,281 shares on a direct basis. The filing was executed by attorney-in-fact John G. Saia on 09/17/2025. The RSU award follows a vesting schedule that began with 25% vesting on October 15, 2022, with the remaining 75% vesting monthly over the following three years.